No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S 1118.5x · 10Y median 1252.6x · 45th percentile · as of Oct 6, 2026
Annualized revenue (TTM) · by quarter, last 23
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T21:48:07.111Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Sera Prognostics, Inc. (SERA) stock was $2.05 as of Oct 6, 2026, 4:00 PM EDT, up 2.50% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -38.3% · 3-year avg -5.9%/yr · 5-year avg -28.9%/yr
Sera Prognostics, Inc. is a women's health diagnostics firm that focuses on creating, advancing, and bringing to market biomarker tests aimed at improving pregnancy results.
Medical - Diagnostics & Research · Salt Lake City, UT
Next Earnings Date
Nov 12, 2026
37 days away
EPS Estimate
-0.14
Revenue Est.
$75000.00
Last Quarter Results
EPS
$-0.18
vs Estimate
$-0.16
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1SERA | $78.29M | $2.05 | +2.50% | -38.32% | -28.91% | N/A | N/A |
| 2INO | $78.07M | $1.13 | -1.74% | -52.51% | -57.05% | -36.78% | vs SERA |
| 3VTVT | $78.59M | $30.03 | -0.99% | +25.71% | -13.55% | -19.77% | vs SERA |
| 4CTOR | $79.03M | $0.85 | -2.69% | -53.61% | N/A | N/A | vs SERA |
| 5NTHI | $77.54M | $2.99 | +2.40% | -74.51% | N/A | N/A | vs SERA |
| 6ACRV | $79.61M | $1.86 | -6.06% | +3.65% | N/A | N/A | vs SERA |
forward FY estimate
N/A
$30000.00
vs Estimate
$71375.00
Consensus Rating
Based on 2 analysts
Average Price Target
$5.50
+168.3% upside
Low
$5.00
Current
$2.05
High
$6.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.20 | $-0.14 | $-0.12 | 2 |
| Quarter ending Dec 2026 | $-0.24 | $-0.17 | $-0.15 | 2 |
| Quarter ending Mar 2027 | $-0.19 | $-0.13 | $-0.11 | 1 |
| Quarter ending Jun 2027 | $-0.19 | $-0.13 | $-0.11 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-0.97 | $-0.66 | $-0.32 | 3 |
| FY 2027 | $-0.79 | $-0.54 | $-0.26 | 3 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $56250.00 | $75000.00 | $93750.00 | 3 |
| Quarter ending Dec 2026 | $111111.00 | $125000.00 | $166666.00 | 2 |
| Quarter ending Mar 2027 | $266666.00 | $300000.00 | $400000.00 | 1 |
| Quarter ending Jun 2027 | $355555.00 | $400000.00 | $533333.00 | 1 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $112500.00 | $225000.00 | $337500.00 | 3 |
| FY 2027 | $1.04M | $1.93M | $2.81M | 3 |
